We demonstrate depletion of endosialin+ stromal cells in subcutaneous and orthotopic tumors and delayed progression in syngeneic murine mammary carcinoma and lung cancer models, highlighting the potential of endosialin-targeting CAR-T cell therapy in multiple solid tumor types. This evidence concerns the gene CD248 and breast carcinoma.